1 year ago..11 Feb 2019 10:43
9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management. The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.